AP
Aurinia Pharmaceuticals Inc
🇺🇸XNAS.AUPHUnited StatesHealthcare
$16.97USDup +0.83 (+5.14%)ClosedDelayed11:24 PM
Price$16.97+0.83 (+5.14%)
Profile
- Healthcare
- Biotechnology
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- CA05156V1022
- CUSIP
- 05156V102
Company
- Employees
- 128
- Headquarters
- Edmonton, United States
- CEO
- Mr. Kevin C. Tang
Market
- Shares outstanding
- 133.1M
- Market cap
- $2.26B
Key dates
- Next earnings
- Nov 3, 2026
Highlights
- Market cap
- $2.15B
- EPS LTM
- $2.36calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- 7.19calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $311.51M+19.76%up year on year
- Net income
- $314.11M+418.03%up year on year
- Gross margin
- 90.36%+0.94%up year on year
- Free cash flow
- $173.58M+87.8%up year on year
Other listings
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.